SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Eidos Therapeutics, Inc. (Nasdaq – EIDX)

BALA CYNWYD – October 5, 2020 /Access Wire/ – Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Eidos Therapeutics, Inc. (“Eidos” or the “Company”) (Nasdaq – EIDX) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the agreement to be acquired by BridgeBio Pharma, Inc. (Nasdaq: BBIO). Under the terms of the agreement, Eidos stockholders will have the right to receive in the transaction, at their election, either 1.85 shares of BridgeBio common stock or $73.26 in cash per Eidos share in the transaction, up to an aggregate maximum of $175 million of cash.

The investigation concerns whether the Eidos Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether BridgBio is paying too little for the Company. For example, at least one wall street analyst has set an $80.00 price target for Eidos shares.

If you own shares of Eidos stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, or call toll free 877-534-2590.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.